Last reviewed: June 29, 2026
Last updated: June 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 receptor agonist therapy like semaglutide requires meeting specific weight and metabolic criteria before starting treatment. PlexusDx evaluates your complete health picture—not just the number on the scale—to determine if compounded semaglutide, tirzepatide, or combination protocols are right for you.
What Are the Weight Criteria for GLP-1 Therapy?
FDA approval for semaglutide (Ozempic, Wegovy) targets adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. Weight-related conditions include type 2 diabetes, high blood pressure, heart disease, and sleep apnea. However, these are clinical guidelines, not absolute barriers—your individual metabolic profile matters more than any single number.
PlexusDx takes a personalized approach by evaluating your BMI alongside your fasting glucose, insulin resistance, blood pressure, lipid levels, and family history of metabolic disease. This comprehensive screening identifies candidates who may benefit from GLP-1 therapy even if they fall slightly below traditional thresholds, or who might need additional metabolic support alongside weight management.
The weight criteria exist because GLP-1 medications work most effectively in people with insulin resistance or dysregulated appetite signals. If you don't fit the strict BMI cutoff but have significant metabolic dysfunction, PlexusDx can still assess your candidacy through your health data and genetic markers.
How BMI and Health Conditions Determine Eligibility
A BMI of 30 or above qualifies as obese by CDC standards and meets baseline eligibility for most GLP-1 therapies. A BMI between 27 and 29.9 qualifies if you have obesity-related comorbidities: type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Your doctor calculates BMI as weight in kilograms divided by height in meters squared, and this single measurement provides a screening tool—not a complete picture of your health.
Beyond BMI, your triglyceride levels, blood glucose patterns, waist circumference, and inflammatory markers reveal whether your body responds well to GLP-1 intervention. Some patients with a BMI near 27 experience significant cardiometabolic risk, while others at BMI 32 may have stable metabolic health. PlexusDx reviews all these factors to create a realistic treatment plan tailored to your unique physiology.
Health conditions amplify eligibility because they indicate that weight loss would meaningfully reduce disease burden. If you have prediabetes or hypertension, even modest weight loss—5 to 10 percent of body weight—can improve blood sugar control and blood pressure. GLP-1 therapy accelerates this benefit by reducing appetite and supporting sustained lifestyle change.
Understanding Genetic Predisposition to Weight and Metabolism
Your genes influence how your body handles hunger signals, energy storage, and glucose metabolism—factors that determine whether you'll respond well to GLP-1 therapy. The Precision Peptide Genetic Test from PlexusDx maps 14 metabolic pathways and analyzes 49 peptides across 150+ genetic insights, including variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), FTO gene (rs9939609), and MC4R gene (rs17782313). These variants predict whether your body will mount a strong response to GLP-1 drugs or whether you may need higher doses or combination therapy.
Genetic testing moves beyond standard weight criteria by revealing your metabolic predispositions. If you carry variants associated with reduced GLP-1 receptor sensitivity, PlexusDx may recommend tirzepatide (a dual GLP-1/GIP agonist) or the GLP-Squared combination protocol instead of semaglutide alone. Conversely, if your peptide genetics show high receptor sensitivity, a lower starting dose of compounded semaglutide may be sufficient—ensuring you pay one flat monthly price while your dose optimizes based on your biology.
Understanding your genetic metabolic profile transforms weight management from guesswork into precision medicine. The Precision Peptide Genetic Test ($99 add-on after your first month) integrates with your clinical data to confirm eligibility and personalize your exact treatment protocol.
Beyond BMI: PlexusDx Personalized Eligibility Assessment
PlexusDx qualifies candidates through a multi-step review: initial health intake, metabolic lab analysis, genetic testing, and physician evaluation. This process ensures you receive the right GLP-1 medication at the right dose—whether that's compounded semaglutide injection starting at $149/month, oral semaglutide at $249/month, tirzepatide injection at $249/month, or combination therapies. Your dose may need to go up as your body adapts. Your price won't.
Unlike insurance-dependent models that apply rigid weight thresholds, PlexusDx serves all 50 states with no insurance requirement and no membership fee. HSA and FSA accounts cover compounded GLP-1 medications, making personalized care accessible regardless of your insurance status. If you've been declined by other providers because your BMI is 28 or 29 but you have metabolic dysfunction, PlexusDx evaluates your full clinical context.
PlexusDx partners exclusively with licensed 503A compounding pharmacies, not 503B facilities, ensuring pharmaceutical-grade quality and customization. The Precision Peptide Genetic Test provides the confidence that your chosen medication—whether microdose GLP-1 protocol at $129/month or premium options—aligns with your genetic capacity to respond.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Precision Peptide Genetic Test starts at $99 add-on. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What BMI do I need to qualify for Ozempic or semaglutide?
The standard threshold is BMI 30 or higher, or BMI 27–29.9 with a weight-related health condition like type 2 diabetes or hypertension. PlexusDx evaluates your complete metabolic profile, not just BMI, so eligibility may differ based on your fasting glucose, insulin resistance, and genetic markers.
What if my BMI is below 30 but I have metabolic issues?
PlexusDx considers candidates below traditional BMI cutoffs if they show insulin resistance, prediabetes, cardiovascular risk factors, or strong family history of metabolic disease. Your Precision Peptide Genetic Test results and lab work inform whether compounded GLP-1 therapy is appropriate and which medication fits your physiology best.
How does the Precision Peptide Genetic Test help with eligibility?
The test ($99 add-on) analyzes your GLP1R, GIPR, FTO, MC4R variants and 14 metabolic pathways to predict your response to semaglutide, tirzepatide, or dual-compound protocols. Strong genetic receptor sensitivity suggests you'll respond well; reduced sensitivity may warrant tirzepatide or combination therapy instead.
Do I need insurance to qualify for PlexusDx GLP-1 therapy?
No. PlexusDx serves all 50 states with no insurance requirement or membership fee. Compounded semaglutide starts at $149/month, tirzepatide at $249/month, and both are HSA/FSA eligible. Your dose may increase over time, but your monthly price remains flat.
What health conditions make me eligible for GLP-1 if my BMI is just below 30?
Type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease all qualify you at BMI 27–29.9. PlexusDx also considers inflammatory markers, waist circumference, and metabolic syndrome as eligibility factors beyond BMI alone.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Mastering the Ozempic Injection Pen: A Comprehensive Guide
Safe and Responsible: Your Comprehensive Guide on How to Dispose of Ozempic Pen and Needles